ALAVERT (loratadine) by Fosun Pharma. Approved for allergic rhinitis, urticaria. First approved in 2002.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
ALAVERT (loratadine) is an oral, orally-disintegrating tablet antihistamine approved in 2002 for allergic rhinitis and urticaria. It is a selective histamine H1-receptor antagonist that provides relief from allergic symptoms by blocking histamine-mediated inflammatory responses. The drug is now in the loss-of-exclusivity (LOE) phase with generic competition intensifying.
As an off-patent small molecule in a crowded OTC/generic landscape, ALAVERT brand teams face margin compression and are typically lean, with focus shifting toward line extensions or deprioritization.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Desloratadine,Phenylephrine Hcl,Ibuprofen Compared to Placebo in Treatment of Symptoms Associated With Common Cold/Flu
A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic Rhinitis, Also Known as Hay Fever in Mexico
A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure
A Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared With Clarityne Tablets
A Study to Assess the Relative Bioavailability of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared to Clarityne Tablets
Worked on ALAVERT at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on ALAVERT offers limited career growth due to its LOE status, generic competition, and flat-to-declining revenue trajectory. Roles are primarily defensive, focused on maintaining market share and managing price erosion rather than driving innovation or expansion. This is ideal for early-career professionals seeking operational exposure in a mature product context, but career advancement typically requires transition to growth-stage or pipeline assets.